atezolitsumaabi

Atezolizumab is a medication used in the treatment of certain types of cancer. It is a type of immunotherapy, specifically an immune checkpoint inhibitor. Atezolizumab works by blocking a protein called PD-L1, which is found on cancer cells and some immune cells. PD-L1 can bind to a receptor called PD-1 on T-cells, which are a type of immune cell. This binding can prevent T-cells from attacking cancer cells. By blocking PD-L1, atezolizumab allows T-cells to more effectively recognize and attack cancer cells.

Atezolizumab is approved for the treatment of several types of cancer, including non-small cell lung cancer, small cell lung cancer, urothelial carcinoma, and certain types of breast cancer. It may be used alone or in combination with other cancer treatments, such as chemotherapy. The decision to use atezolizumab and the specific dosage and schedule are determined by a healthcare professional based on the type and stage of cancer, as well as the patient's overall health.

Like all medications, atezolizumab can cause side effects. Common side effects may include fatigue, rash, nausea, itching, and decreased appetite. More serious side effects can occur, including immune-related adverse events, where the immune system attacks healthy tissues and organs. These can affect various parts of the body, such as the lungs, liver, intestines, and endocrine glands. Patients are closely monitored for side effects during treatment.